Tezampanel (PRN-001-01)
Opioid Use Disorder (Opiate Withdrawal Syndrome)
Phase 1Active
Key Facts
About Proniras
Proniras is a private, clinical-stage biotech targeting the significant unmet need in opioid use disorder (OUD) treatment with its lead candidate, tezampanel (PRN-001-01). The company's approach modulates glutaminergic signaling to address withdrawal and addiction, a novel mechanism that avoids opioid receptor interaction. With a seasoned leadership team and recent Series B financing, Proniras is positioned to advance tezampanel through Phase 1 clinical trials. Its strategy is supported by non-dilutive funding from grants like those from the National Institute on Drug Abuse (NIDA).
View full company profile